Comparing an investigational eye injection to Eylea for wet AMD
Part of Eyes & vision clinical trials.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have active wet AMD in one eye, with leaking fluid under or in the retina.
- Your vision in the study eye must be between 34 and 73 letters on an eye chart (roughly 20/40 to 20/200).
- You must not have had any prior treatment for wet AMD in the study eye.
- You must be able to attend regular clinic visits and receive eye injections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests a new eye injection (called QL1207H) against aflibercept, a standard treatment for wet macular degeneration. The goal is to see if the new drug is as effective in improving vision and reducing fluid in the eye.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.